Journal Article

Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase‐3β

Molnár, Andor, Thiemermann, Christoph, Collin, Marika, Varga, Csaba, Pósa, Anikó, Whittle, Brendan J R

2006

Overview

The effects of the inhibitors of glycogen synthase kinase‐3β (GSK‐3β), TDZD‐8 and SB 415286, which can substantially reduce the systemic inflammation associated with endotoxic shock in vivo, have now been investigated on the acute colitis provoked by trinitrobenzene sulphonic acid (TNBS) in the rat. Administration of the GSK‐3β inhibitor TDZD‐8 (0.1, 0.33 or 1.0 mg kg−1, s.c., b.i.d., for 3 days) caused a dose‐dependent reduction in the colonic inflammation induced by intracolonic TNBS assessed after 3 days, both as the area of macroscopic involvement and as a score using 0–10 scale. Likewise, following administration of the GSK‐3β inhibitor SB 415286 (0.1, 0.33 or 1.0 mg kg−1, s.c., b.i.d., for 3 days), the extent and degree of the TNBS‐provoked colonic inflammation was reduced. Administration of either TDZD‐8 or SB 415286 reduced the fall in body weight following challenge with TNBS at each dose level studied. The increase in myeloperoxidase activity, an index of neutrophil infiltration into the TNBS‐induced inflamed colon, was significantly inhibited by both TDZD‐8 and SB 415286 at each dose level. The increase in the levels of the proinflammatory cytokine, TNF‐α, in the inflamed colon was also significantly inhibited by either compound at the highest doses evaluated. The elevated levels of the transcription factor NF‐κB subunit p65, as determined by Western blot in the nuclear extracts from the TNBS‐provoked inflamed colonic tissue, were dose‐dependently reduced by TDZD‐8 or SB 415286 treatment. These findings demonstrate that two chemically distinct selective inhibitors of the activity of GSK‐3β reduce the inflammation and tissue injury in a rat model of acute colitis. The mechanisms underlying this anti‐inflammatory action may be related to downregulation of NF‐κB activity, involved in the generation of proinflammatory mediators. British Journal of Pharmacology (2006) 147, 575–582. doi:10.1038/sj.bjp.0706509

• Publisher: Blackwell Publishing Ltd,Nature Publishing,Nature Publishing Group
• Subject: Biological and medical sciences / Glycogen synthase kinase‐3β / GSK‐3β inhibitors / Medical sciences / NF‐κB / NF‐κB p65 / Pharmacology. Drug treatments / SB 415286 / TDZD‐8 / TNBS colitis / TNF‐α